Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy-Reference-Cited by-同舟云学术

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy

Published:2007-11-23 Issue:3 Volume:167 Page:267-277
ISSN:0340-6199
Container-title:European Journal of Pediatrics
language:en
Short-container-title:Eur J Pediatr

Author:

Wraith J. Edmond,Scarpa Maurizio,Beck Michael,Bodamer Olaf A.,De Meirleir Linda,Guffon Nathalie,Meldgaard Lund Allan,Malm Gunilla,Van der Ploeg Ans T.,Zeman Jiri

Publisher

Springer Science and Business Media LLC

Subject

Pediatrics, Perinatology and Child Health

Link

http://link.springer.com/content/pdf/10.1007/s00431-007-0635-4

Reference40 articles.

1. Baehner F, Schmiedeskamp C, Krummenauer F, Miebach E, Bajbouj M, Whybra C, Kohlschutter A, Kampmann C, Beck M (2005) Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 28:1011–1017

2. Beck M, Cole G (1984) Disc oedema in association with Hunter’s syndrome: ocular histopathological findings. Br J Ophthalmol 68:590–594

3. Bondeson ML, Dahl N, Malmgren H, Kleijer WJ, Tonnesen T, Carlberg BM, Pettersson U (1995) Inversion of the IDS gene resulting from recombination with IDS-related sequences is a common cause of the Hunter syndrome. Hum Mol Genet 4:615–621

4. Brama I, Gay I, Feinmesser R, Springer C (1986) Upper airway obstruction in Hunter syndrome. Int J Pediatr Otorhinolaryngol 11:229–235

5. Casal M, Haskins M (2006) Large animal models and gene therapy. Eur J Hum Genet 14:266–272

Cited by 410 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of early treatment with intravenous idursulfase and intrathecal idursulfase‐IT on cognitive function in siblings with neuronopathic mucopolysaccharidosis II;Journal of Inherited Metabolic Disease;2024-09-09

2. Genotype–phenotype findings in patients with mucopolysaccharidosis II from the Hunter Outcome Survey;Molecular Genetics and Metabolism;2024-09

3. Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond;BioDrugs;2024-08-23

4. Long‐term cardiovascular outcomes and mortality with enzyme replacement therapy in patients with mucopolysaccharidosis type II;Journal of Inherited Metabolic Disease;2024-07-30

5. Causes of death in mucopolysaccharidoses;Molecular Genetics and Metabolism;2024-07